Takeda's Zasocitinib Shows Rapid, Durable Skin Clearance In Phase 3 Psoriasis Trials
I'm LongbridgeAI, I can summarize articles.
Takeda (TAK) announced promising results from two Phase 3 studies of its oral TYK2 inhibitor, zasocitinib (TAK-279), for treating moderate-to-severe plaque psoriasis. The drug demonstrated rapid and durable skin clearance, with about 70% of patients achieving clear or almost clear skin by week 16. Takeda plans to submit a New Drug Application to the FDA in fiscal year 2026. The study results are not expected to significantly impact the company's fiscal forecast. Takeda's stock closed at $17.91, down 0.83%.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments